CG Oncology, Inc. financial data

Symbol
CGON on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
400 Spectrum Center Drive, Suite 2040, Irvine, CA
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-K - Q4 2024 - Mar 28, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 4.16K %
Debt-to-equity 2.48 %
Return On Equity -14.7 % -131%
Return On Assets -14.4 %

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 76.2M shares +14.4%
Common Stock, Shares, Outstanding 76.2M shares +1358%
Entity Public Float 1.4B USD
Common Stock, Value, Issued 8K USD
Weighted Average Number of Shares Outstanding, Basic 62.5M shares +1343%
Weighted Average Number of Shares Outstanding, Diluted 62.5M shares +1343%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 82.1M USD +79.5%
General and Administrative Expense 33.7M USD +240%
Operating Income (Loss) -115M USD -107%
Nonoperating Income (Expense) 26.6M USD +289%
Net Income (Loss) Attributable to Parent -88M USD -81.1%
Earnings Per Share, Basic -1.41 USD/shares +91%
Earnings Per Share, Diluted -1.41 USD/shares +91%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 257M USD +3010%
Marketable Securities, Current 485M USD +170%
Assets, Current 754M USD +289%
Property, Plant and Equipment, Net 272K USD +294%
Operating Lease, Right-of-Use Asset 221K USD -47.6%
Other Assets, Noncurrent 94K USD +395%
Assets 755M USD +279%
Accounts Payable, Current 6.52M USD +101%
Liabilities, Current 21.4M USD +49.9%
Operating Lease, Liability, Noncurrent 52K USD -78.7%
Liabilities 21.4M USD +47.6%
Retained Earnings (Accumulated Deficit) -218M USD -67.8%
Stockholders' Equity Attributable to Parent 733M USD
Liabilities and Equity 755M USD +279%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -26M USD -226%
Net Cash Provided by (Used in) Financing Activities 403M USD
Net Cash Provided by (Used in) Investing Activities -307M USD -291%
Common Stock, Shares Authorized 700M shares +41.8%
Common Stock, Shares, Issued 76.2M shares +1358%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 69.2M USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 257M USD +3010%
Deferred Tax Assets, Valuation Allowance 56.4M USD +85.2%
Deferred Tax Assets, Gross 56.5M USD +84.8%
Operating Lease, Liability 238K USD
Payments to Acquire Property, Plant, and Equipment 12K USD
Lessee, Operating Lease, Liability, to be Paid 239K USD
Operating Lease, Liability, Current 186K USD -14.3%
Lessee, Operating Lease, Liability, to be Paid, Year Two 52K USD
Lessee, Operating Lease, Liability, to be Paid, Year One 187K USD
Operating Lease, Weighted Average Discount Rate, Percent 0.02 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 1K USD
Deferred Tax Assets, Operating Loss Carryforwards 34.6M USD +92.1%
Unrecognized Tax Benefits 1.4M USD +39.7%
Operating Lease, Payments 223K USD +1.83%
Additional Paid in Capital 951M USD +13805%
Depreciation, Depletion and Amortization 4K USD 0%
Deferred Tax Assets, Net of Valuation Allowance 56.4M USD +85.2%
Share-based Payment Arrangement, Expense 11.4M USD +646%